Join

Compare · BSX vs FEMY

BSX vs FEMY

Side-by-side comparison of Boston Scientific Corporation (BSX) and Femasys Inc. (FEMY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BSX and FEMY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BSX is the larger of the two at $72.39B, about 222.4x FEMY ($325.5M).
  • Over the past year, BSX is down 51.3% and FEMY is down 66.3% - BSX leads by 15.0 points.
  • BSX has been more active in the news (12 items in the past 4 weeks vs 2 for FEMY).
  • BSX has more recent analyst coverage (25 ratings vs 3 for FEMY).
PerformanceBSX-51.31%FEMY-66.33%
2025-06-09+0.00%2026-06-08
MetricBSXFEMY
Company
Boston Scientific Corporation
Femasys Inc.
Price
$48.71+0.31%
$5.37+1661.23%
Market cap
$72.39B
$325.5M
1M return
-13.91%
-40.01%
1Y return
-51.31%
-66.33%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
12
2
Recent ratings
25
3
BSX

Boston Scientific Corporation

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

FEMY

Femasys Inc.

Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Latest BSX

Latest FEMY